LLY

1,120.29

-0.83%↓

JNJ

235.16

-0.31%↓

ABBV

222.63

+0.73%↑

UNH

408.01

-0.62%↓

MRK

115.09

+0.17%↑

LLY

1,120.29

-0.83%↓

JNJ

235.16

-0.31%↓

ABBV

222.63

+0.73%↑

UNH

408.01

-0.62%↓

MRK

115.09

+0.17%↑

LLY

1,120.29

-0.83%↓

JNJ

235.16

-0.31%↓

ABBV

222.63

+0.73%↑

UNH

408.01

-0.62%↓

MRK

115.09

+0.17%↑

LLY

1,120.29

-0.83%↓

JNJ

235.16

-0.31%↓

ABBV

222.63

+0.73%↑

UNH

408.01

-0.62%↓

MRK

115.09

+0.17%↑

LLY

1,120.29

-0.83%↓

JNJ

235.16

-0.31%↓

ABBV

222.63

+0.73%↑

UNH

408.01

-0.62%↓

MRK

115.09

+0.17%↑

Search

Geron Corp

Open

SectorHealthcare

1.17 0.86

Overview

Share price change

24h

Current

Min

1.13

Max

1.17

Key metrics

By Trading Economics

Income

25M

-3.6M

Sales

3.8M

52M

EPS

-0.005

Profit margin

-7.026

Employees

258

EBITDA

24M

90K

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+247.83% upside

Dividends

By Acuity

Next Earnings

5 Aug 2026

Market Stats

By TradingEconomics

Market Cap

-281M

725M

Previous open

0.31

Previous close

1.17

News Sentiment

By Acuity

55%

45%

280 / 342 Healthcare

Geron Corp Chart

Past performance is not a reliable indicator of future results.

About Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
help-icon Live chat